AVEO stock: buy or sell?

AVEO stock price: $0.98 2.08% At close on September 20th, 2019

Updated on:
September 20th, 2019

2

AVEO Pharmaceuticals shares rose 2.08% to $0.98 today. On Sep/18 AVEO plummed a chilling -6.06%. On Tuesday AVEO skyrocketed an amazing 5.71%.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF\u002Fc-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study.

Should I buy AVEO stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with AVEO stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean AVEO will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is AVEO Pharmaceuticals stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 11 ratings published for AVEO stock in the last 30 days.

Is AVEO a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-11HC WainwrightNeutralBuy
2019-9-10Piper Jaffray Companiesn/aOverweight
2019-3-28National Securitiesn/aSell
2019-3-18HC Wainwrightn/aHold
2019-2-4B. RileyBuyNeutral
2019-2-4B. RileyBuyNeutral
2019-2-1HC WainwrightBuyNeutral
2019-2-1HC WainwrightBuyNeutral
2019-1-8B. Rileyn/aBuy
2019-1-31Piper Jaffray Companiesn/aOverweight
2019-1-14HC Wainwrightn/aBuy

AVEO stock analysis

Daily outlook

AVEO Pharmaceuticals ended today at $0.98 and rose a remarkable 2.08%.

AVEO Pharmaceuticals shares rose 2.08% to $0.98 today. From a daily perspective, AVEO is in a short term uptrend after plotting its last bottom ($0.85, on Sep/13) higher than the previous bottom, and its last top ($1.12, on Tuesday) also over the previous top. Now trading in between its last bottom and last top AVEO might consolidate in a plain range, waiting to break out over $1.12 or down under $0.85.

AVEO stock chart (daily)

Weekly outlook

After boosting an astounding 27.66% in a week last week, AVEO Pharmaceuticals closed this week at $0.98 and soared a cool 4.26%. Early August AVEO plummed a bloodcurdling -6.15% in just one week.

Since last week when AVEO stock price broke up the SMA40w line, it gained $0.30 (44.12%).

AVEO stock chart (weekly)

AVEO stock price history

AVEO IPO was on March 12th, 2010 at $8.25 per share1. Since then, AVEO stock lost a -88.10%, with a yearly average of -9.80%.

1: Adjusted price after possible price splits or reverse-splits.

AVEO stock historical price chart

AVEO stock reached 52-week highs on September at $3.59, and all-time highs 2011-07-06 with a price of 21.55.

AVEO stock price target is $2.80

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 10 price targets for AVEO stock:
AVEO stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-11HC WainwrightUpgrades$1.00$1.7575%
2019-9-10Piper Jaffray CompaniesRaises Target$3.00$4.0033.3%
2019-3-18HC WainwrightReiteratesn/a$1.00-
2019-2-4B. RileyReiterates$5.00$1.00-80%
2019-2-4B. RileyDowngrades$5.00$1.00-80%
2019-2-1HC WainwrightReiteratesn/a$1.00-
2019-2-1HC WainwrightDowngradesn/a$1.00-
2019-1-8B. RileyInitiatesn/a$5.00-
2019-1-31Piper Jaffray CompaniesReiterates$5.00$3.00-40%
2019-1-14HC WainwrightReiteratesn/a$9.00-
(in average)$3.80$2.80-26.0%
Moving in a range from $9.00 and $1.00, the price forecast for AVEO Pharmaceuticals stock is $2.80. In average, analysts' outlook on AVEO price target is negative, reducing the prediction by a -26.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

AVEO let down analysts on March when it published an Earnings per Share (EPS) of $-0.03 when the market consensus was $-0.06.
AVEO earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.12n/a
2017-Q2-n/a-0.3n/a
2017-Q3-n/a-0.22n/a
2017-Q42018-03-13-0.02-0.08n/a
2018-Q12018-05-08-0.07-0.08n/a
2018-Q22018-08-07-0.06-0.15n/a
2018-Q32018-11-09-0.06-0.05n/a
2018-Q42019-03-14-0.06-0.03n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, AVEO Pharmaceuticals annual turnover collapsed a spooky -28.63% to $5.41 million USD from $7.58 marked in 2017. On the other hand, its earnings margin (compared to sales) rocketed to -98.52%, that is $-5.33 million.

AVEO annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$1.29 M-$-107.03 M-8296.9%-
2014$18 M1,304.88%$-52.74 M-291.0%-50.73%
2015$19 M4.97%$-15.00 M-78.9%-71.56%
2016$2.52 M-86.78%$-26.89 M-1069.1%79.23%
2017$7.58 M201.35%$-65.03 M-858.0%141.85%
2018$5.41 M-28.63%$-5.33 M-98.5%-91.80%

Quarterly financial results

AVEO Pharmaceuticals reported $1.48 million in revenues for 2018-Q4, a -39.89% less compared to previous quarter. Reported quarter earnings marked $21.82 M with a profit margin of 1,471.21%. Profit margin skyrocketed a 2,369.59% compared to previous quarter when profit margin was -898.38%. When comparing turnover to same quarter last year, AVEO sales marked an amazing gain and climbed a 1,708.54%.
AVEO quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$2.53 M-$-8.84 M-349.4%-
2017-Q2$0.35 M-86.13%$-33.29 M-9484.3%276.58%
2017-Q3$4.61 M1,214.53%$-26.40 M-572.1%-20.71%
2017-Q4$0.08 M-98.22%$3.50 M4267.1%-113.26%
2018-Q1$1.03 M1,151.22%$-8.99 M-876.0%-356.87%
2018-Q2$0.43 M-57.80%$4.00 M924.7%-144.55%
2018-Q3$2.47 M469.75%$-22.16 M-898.4%-653.52%
2018-Q4$1.48 M-39.89%$21.82 M1471.2%-198.44%

AVEO ownership

When you are planning to invest in shares of a company, it's always worth to overview its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For AVEO Pharmaceuticals, 0.28% of all outstanding shares are owned by its staff.

In case of AVEO stock, 32.51% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AVEO stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to AVEO Pharmaceuticals:

AVEOAMGNARQLBIIBBMY
Market cap$157.5 M$118.1 B$964.5 M$44.0 B$82.9 B
Total shares160.7 M599.7 M120.3 M184.5 M1,640.0 M
Float shares134.8 M598.3 M93.2 M184.0 M1,630.0 M
  - Institutional holdings (%)32.5%81.9%81.2%93.4%75.0%
  - Insider holdings (%)0.3%0.2%1.7%0.5%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

AVEO summary

Friday, September 20th, 2019
Open$0.96
Close$0.98
Day range$0.95 - $1.01
Previous close$0.96
Session gain2.08%
Average true range$0.09
50d mov avg$0.73
100d mov avg$0.74
200d mov avg$0.96
Daily patternlt06a
Weekly pattern

AVEO performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For AVEO Pharmaceuticals, the comparison is made against Amgen, ArQule, Biogen, Bristol-Myers Squibb, Eli Lilly and, Merrimack Pharmaceuticals and Regeneron Pharmaceuticals.
Stock3m6m12m
AVEOAVEO Pharmaceutic...28.95%68.97%-65.73%
AMGNAmgen6.00%7.15%-1.03%
ARQLArQule-23.55%66.39%57.87%
BIIBBiogen-0.13%10.19%-30.87%
BMYBristol-Myers Squ...3.39%6.87%-16.14%
LLYEli Lilly and1.14%-8.44%11.63%
MACKMerrimack Pharmac...79.69%52.48%83.07%
REGNRegeneron Pharmac...-7.62%-24.48%-24.19%

AVEO competitors

We selected a few stocks to conform a list of AVEO Pharmaceuticals competitors to examine if you are interested in investing in AVEO: